The scientific logic behind this drug repositioning effort is elegant. BM212 is a 1,3,5-trisubstituted pyrrole originally identified during a phenotypic screen of azole, imidazole, pyrrole, and toluidine derivatives against Mycobacterium tuberculosis, where it displayed a minimal inhibitory concentration of 5 micromolar against drug-sensitive strains and 8 micromolar against multidrug-resistant strains. Whole-genome sequencing of resistant mutants later revealed that BM212 acts by directly binding MmpL3, an essential inner membrane protein involved in trehalose monomycolate flipping during mycobacterial cell wall biosynthesis. Meanwhile, a structurally related pyrazole compound, MMV1580843, had emerged from a parallel screen of the Medicines for Malaria Venture Pandemic Response Box as a hit with striking stage-specific activity against late-stage gametocytes, showing a half-maximal inhibitory concentration of 0.11 micromolar while being comparatively inactive against asexual blood-stage parasites. Recognizing the considerable structural similarity between the two molecules, the team hypothesized that the BM212 pyrrole scaffold could be systematically optimized to yield antiplasmodial activity across the parasite life cycle.

The medicinal chemistry campaign was deliberately modular. The researchers synthesized a focused library of 33 compounds, keeping the central pyrrole core constant while systematically varying substituents at three positions: N1, C5, and C3. The synthetic strategy relied on a Stetter reaction between methyl vinyl ketone and appropriate benzaldehydes to generate 1,4-diketones, which were then cyclized with corresponding amines to afford 1,5-disubstituted pyrroles. A subsequent Mannich reaction with formaldehyde and amines introduced the C3 cyclic amine substituents. This efficient, step-economical route enabled rapid access to structurally diverse derivatives in good overall yields, providing a sufficiently diverse compound set to support a comprehensive structure-activity relationship investigation. Several compounds had been previously reported as BM212 analogues evaluated for antitubercular activity, but they were deliberately resynthesized and re-evaluated within the present work to enable a coherent SAR analysis in the antiplasmodial context.

Biological profiling was conducted across multiple life cycle stages using rigorous, orthogonal assays. Activity against asexual blood-stage parasites of the drug-sensitive NF54 strain was measured using a SYBR Green I fluorescence assay, detecting parasite proliferation after 96 hours of drug pressure. Compounds with IC50 values below 1 micromolar were additionally profiled against the multidrug-resistant Dd2 strain to assess cross-resistance potential. Late-stage gametocyte activity was evaluated using PrestoBlue fluorescence or flow cytometric readouts with MitoTracker Deep Red staining, while cytotoxicity was assessed against a human hepatocellular carcinoma line, Hep G2. All IC50 values were calculated through nonlinear regression using a four-parameter logistic dose-response model, with all data reported from a minimum of three independent biological replicates performed in technical triplicates. Assay reproducibility was confirmed by Z-factors all exceeding 0.8, ensuring the reliability of the SAR conclusions drawn from the dataset.

The first and most striking SAR trend concerned the C3 cyclic amine, which emerged as the dominant driver of life cycle stage preference. BM212 itself, bearing an N-methylpiperazine at C3, displayed more than 50-fold increased activity against late-stage gametocytes over asexual parasites, with an IC50 of 0.18 micromolar against gametocytes while being inactive above 10 micromolar against both NF54 and Dd2 asexual stages. When the researchers replaced this piperazine with a morpholine or a 4,4-difluoropiperidine, gametocytocidal activity collapsed, but measurable activity against asexual blood stages was retained. In contrast, the dimethyl-azasilinane analogue, compound 1, retained potent gametocytocidal activity with an IC50 of 0.48 micromolar while displaying improved activity against asexual parasites with an IC50 of 1.08 micromolar, suggesting that dual-stage activity can indeed be achieved within the BM212 pyrrole scaffold, in contrast to the structurally related pyrazole MMV’843, which predominantly displays gametocytocidal activity.

Further optimization focused on the electronic properties of the N1 and C5 substituents. Electron-deficient aryl groups such as 4-fluorophenyl and 2-trifluoromethylphenyl consistently enhanced potency and improved physicochemical properties across the series. In the methylpiperazine series, the difluorinated analogue, compound 7, achieved a remarkable IC50 of 0.093 micromolar against late-stage gametocytes, a twofold improvement over BM212 itself, while simultaneously delivering a fourfold improvement in asexual blood-stage activity relative to the parent compound. Aqueous solubility also improved dramatically, reaching 185 micromolar for compound 7 compared with just 10 micromolar for BM212. However, a clear limitation emerged: simultaneously reducing lipophilicity at both N1 and C5, for example by introducing pyridyl rings at both positions, proved detrimental to biological activity, with compound 12 showing a greater than 30-fold reduction in potency against both life cycle stages. This finding underscores the delicate balance between polarity and hydrophobic fit that governs activity in this scaffold.

The morpholine series provided additional SAR insights from a bioisosteric perspective. Morpholine is a privileged heterocycle commonly used in medicinal chemistry to reduce basicity relative to piperazine, improve metabolic stability, and introduce an additional hydrogen-bond acceptor through its ether oxygen. Although the initial morpholine analogue showed limited activity against both asexual parasites and gametocytes, subsequent modifications led to modest improvements in asexual blood-stage activity, with compounds 18 through 20 displaying IC50 values below 2.5 micromolar. Potent gametocytocidal activity was restored by introducing fluorophenyl substituents, with compounds 25, 26, and 32 all retaining sub-micromolar activity against late-stage gametocytes. Notably, exchanging the N1 and C5 substituents between compounds 32 and 33 resulted in a marked change in biological profile, indicating that the positional arrangement of these substituents strongly influences activity. The difluorophenyl analogue, compound 26, exhibited substantially improved aqueous solubility of 180 micromolar compared with less than 5 micromolar for the parent morpholine analogue.

Resistance profiling and transmission-blocking evaluation provided the most compelling translational evidence. Several optimized analogues retained activity against the multidrug-resistant Dd2 strain, with IC50 values ranging from 1.01 to 1.54 micromolar and less than threefold differences in potency relative to the drug-sensitive NF54 strain. This sensitivity profile implies that mutations in the chloroquine resistance transporter PfCRT, antifolate resistance mutations, or copy number variation in the multidrug resistance transporter do not confer resistance to the compounds evaluated here, a critical consideration given the de novo development of artemisinin kelch-13 resistance mutations in African parasite populations. In the standard membrane feeding assay, compound 9 achieved 81 percent transmission-reducing activity, while BM212 itself achieved 62 percent. Interestingly, both compounds showed a markedly stronger effect on female gamete formation than on male gamete exflagellation, a profile that differs from many antimalarial candidates and may suggest a mechanism of action distinct from compounds that primarily interfere with cell division during male gametogenesis.

The molecular target of these compounds in Plasmodium remains unknown, and this represents both a challenge and an opportunity. Plasmodium does not possess an MmpL3 homolog, the primary target of BM212 in mycobacteria, so the antiplasmodial activity must arise through a different mechanism. Interestingly, other well-known MmpL3 inhibitors such as ethambutol and the ethylenediamine SQ109 have previously also shown activity against P. falciparum parasites with a similar preference towards late-stage gametocytes, although the involvement of resistance nodulation-division superfamily proteins has been excluded for these compounds, pointing instead to ionophore activity. The researchers propose that enhanced evolution techniques to select for resistant parasites, thermal protein profiling, or chemical pulldown proteomics using labelled versions of lead compounds could directly identify protein target engagement in the parasites. Determining the minimum inoculum of resistance for this series would also be important to evaluate their potential propensity to resistance.

Overall, this work positions BM212-derived pyrroles as a promising and versatile multistage antiplasmodial chemotype while delineating the key structural determinants required to achieve potency, selectivity, and transmission-blocking efficacy. The scaffold now stands ready for a formal hit-to-lead campaign, where the effects of structural changes on active compounds must be investigated in light of enhanced metabolic stability in microsomes and hepatocytes, leading to pharmacokinetic characterization and in vivo efficacy studies to assess the potential of early lead antimalarial candidates. Given that malaria elimination will require a multipronged approach including recently recommended vaccines such as RTS,S and R21/Matrix-M, together with strategies aimed at blocking parasite transmission, chemotypes that target both asexual blood-stage parasites and mature gametocytes offer genuine promise for reducing transmission rates and preventing the spread of resistance once it has developed in the asexual stages. The BM212 pyrrole scaffold, born from tuberculosis drug discovery and reborn through systematic antiplasmodial optimization, may yet contribute meaningfully to that effort.

Subject of Research: Probing the activity of BM212, an antimycobacterial, and its derivatives against multiple life cycle stages of Plasmodium falciparum

Article Title: Probing the activity of BM212, an antimycobacterial, and its derivatives against multiple life cycle stages of Plasmodium falciparum

Article References: Salvucci, B., van der Watt, M., Tammaro, C., Guida, M., Pantaleo, L., Reader, J., Rabie, T., Tshabalala, S., Naude, M., Venter, N., Welcome, T., Erlank, E., Koekemoer, L. L., Biava, M., Birkholtz, L.-M., & Poce, G. (2026). Probing the activity of BM212, an antimycobacterial, and its derivatives against multiple life cycle stages of Plasmodium falciparum. Frontiers in Drug Discovery, 6, Article 1919483. https://doi.org/10.3389/fddsv.2026.1919483

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1919483

Keywords: Probing, activity, BM212, antimycobacterial, derivatives, against, multiple, life, cycle, stages, Plasmodium, falciparum